ICCC
Price
$6.80
Change
+$0.05 (+0.74%)
Updated
Jun 30, 10:32 AM (EDT)
Capitalization
61M
38 days until earnings call
NERV
Price
$1.72
Change
-$0.04 (-2.27%)
Updated
Jun 30, 12:14 PM (EDT)
Capitalization
12.45M
43 days until earnings call
Interact to see
Advertisement

ICCC vs NERV

Header iconICCC vs NERV Comparison
Open Charts ICCC vs NERVBanner chart's image
ImmuCell
Price$6.80
Change+$0.05 (+0.74%)
Volume$455
Capitalization61M
Minerva Neurosciences
Price$1.72
Change-$0.04 (-2.27%)
Volume$900
Capitalization12.45M
ICCC vs NERV Comparison Chart in %
Loading...
ICCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ICCC vs. NERV commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ICCC is a Hold and NERV is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ICCC: $6.75 vs. NERV: $1.76)
Brand notoriety: ICCC and NERV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ICCC: 71% vs. NERV: 105%
Market capitalization -- ICCC: $61M vs. NERV: $12.45M
ICCC [@Biotechnology] is valued at $61M. NERV’s [@Biotechnology] market capitalization is $12.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ICCC’s FA Score shows that 0 FA rating(s) are green whileNERV’s FA Score has 0 green FA rating(s).

  • ICCC’s FA Score: 0 green, 5 red.
  • NERV’s FA Score: 0 green, 5 red.
According to our system of comparison, NERV is a better buy in the long-term than ICCC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ICCC’s TA Score shows that 3 TA indicator(s) are bullish while NERV’s TA Score has 3 bullish TA indicator(s).

  • ICCC’s TA Score: 3 bullish, 5 bearish.
  • NERV’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ICCC is a better buy in the short-term than NERV.

Price Growth

ICCC (@Biotechnology) experienced а -11.18% price change this week, while NERV (@Biotechnology) price change was -0.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.68%. For the same industry, the average monthly price growth was +32.95%, and the average quarterly price growth was +6.81%.

Reported Earning Dates

ICCC is expected to report earnings on Aug 07, 2025.

NERV is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+3.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ICCC($61M) has a higher market cap than NERV($12.4M). ICCC YTD gains are higher at: 31.068 vs. NERV (-20.778). NERV has higher annual earnings (EBITDA): 8.58M vs. ICCC (2.94M). NERV has more cash in the bank: 17.3M vs. ICCC (4.6M). NERV has less debt than ICCC: NERV (0) vs ICCC (14.7M). ICCC has higher revenues than NERV: ICCC (27.3M) vs NERV (0).
ICCCNERVICCC / NERV
Capitalization61M12.4M492%
EBITDA2.94M8.58M34%
Gain YTD31.068-20.778-150%
P/E RatioN/A2.16-
Revenue27.3M0-
Total Cash4.6M17.3M27%
Total Debt14.7M0-
FUNDAMENTALS RATINGS
ICCC vs NERV: Fundamental Ratings
ICCC
NERV
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
42
Fair valued
PROFIT vs RISK RATING
1..100
75100
SMR RATING
1..100
90100
PRICE GROWTH RATING
1..100
3960
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NERV's Valuation (42) in the Biotechnology industry is somewhat better than the same rating for ICCC (88) in the Medical Specialties industry. This means that NERV’s stock grew somewhat faster than ICCC’s over the last 12 months.

ICCC's Profit vs Risk Rating (75) in the Medical Specialties industry is in the same range as NERV (100) in the Biotechnology industry. This means that ICCC’s stock grew similarly to NERV’s over the last 12 months.

ICCC's SMR Rating (90) in the Medical Specialties industry is in the same range as NERV (100) in the Biotechnology industry. This means that ICCC’s stock grew similarly to NERV’s over the last 12 months.

ICCC's Price Growth Rating (39) in the Medical Specialties industry is in the same range as NERV (60) in the Biotechnology industry. This means that ICCC’s stock grew similarly to NERV’s over the last 12 months.

NERV's P/E Growth Rating (99) in the Biotechnology industry is in the same range as ICCC (100) in the Medical Specialties industry. This means that NERV’s stock grew similarly to ICCC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ICCCNERV
RSI
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
78%
Bearish Trend 4 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 4 days ago
78%
Advances
ODDS (%)
Bullish Trend 18 days ago
76%
N/A
Declines
ODDS (%)
Bearish Trend 13 days ago
76%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
72%
Bullish Trend 4 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ICCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NERV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SMMYY6.160.30
+5.12%
Sumitomo Metal Mining Co., Ltd.
FSDK63.00N/A
N/A
First Citizens National Bank of Upper Sandusky (The) (OH)
ALGGY6.99N/A
N/A
Alliance Global Group, Inc.
DVLN3600.00N/A
N/A
DVL, Inc.
ECSNF3.05N/A
N/A
Ecosynthetix, Inc.

ICCC and

Correlation & Price change

A.I.dvisor tells us that ICCC and MYNDF have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ICCC and MYNDF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICCC
1D Price
Change %
ICCC100%
-0.59%
MYNDF - ICCC
24%
Poorly correlated
N/A
NERV - ICCC
23%
Poorly correlated
-2.22%
TRAW - ICCC
23%
Poorly correlated
N/A
RLYB - ICCC
23%
Poorly correlated
-8.25%
MNOV - ICCC
22%
Poorly correlated
+2.31%
More

NERV and

Correlation & Price change

A.I.dvisor indicates that over the last year, NERV has been loosely correlated with ASPHF. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if NERV jumps, then ASPHF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NERV
1D Price
Change %
NERV100%
-2.22%
ASPHF - NERV
44%
Loosely correlated
N/A
DNLI - NERV
35%
Loosely correlated
-2.69%
TCRX - NERV
34%
Loosely correlated
-5.41%
ANAB - NERV
33%
Loosely correlated
-3.89%
ETNB - NERV
31%
Poorly correlated
-0.90%
More